mitochondrial complex I deficiency, nuclear type 18

disease
On this page

Also known as MC1DN18

Summary

mitochondrial complex I deficiency, nuclear type 18 (MONDO:0032623) is a disease caused by NDUFAF3 (GenCC Strong), with 1 cohort gene.

At a glance

  • Causal gene: NDUFAF3 (GenCC Strong)
  • Cohort genes: 1
  • ClinVar variants: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemitochondrial complex I deficiency, nuclear type 18
Mondo IDMONDO:0032623
OMIM618240
DOIDDOID:0112070
UMLSC4748790
MedGen1648321
GARD0016325
Is cancer (heuristic)no

Also known as: MC1DN18

Data availability: 15 ClinVar variants · 3 GenCC gene-disease records.

Disease family

Classification path: disease › human disease › disease by developmental or physiological process › metabolic diseasedevelopmental anomaly of metabolic origininborn mitochondrial metabolism disordermitochondrial oxidative phosphorylation disordermitochondrial respiratory chain complex deficiencymitochondrial complex I deficiencymitochondrial complex I deficiency, nuclear typemitochondrial complex I deficiency, nuclear type 18

Related subtypes (36): mitochondrial complex I deficiency, nuclear type 12, mitochondrial complex I deficiency, nuclear type 30, Leber hereditary optic neuropathy, autosomal recessive, mitochondrial complex I deficiency, nuclear type 36, mitochondrial complex I deficiency, nuclear type 37, mitochondrial complex I deficiency, nuclear type 2, mitochondrial complex I deficiency, nuclear type 3, mitochondrial complex I deficiency, nuclear type 4, mitochondrial complex I deficiency, nuclear type 5, mitochondrial complex I deficiency, nuclear type 6, mitochondrial complex I deficiency, nuclear type 7, mitochondrial complex I deficiency, nuclear type 8, mitochondrial complex I deficiency, nuclear type 9, mitochondrial complex I deficiency, nuclear type 10, mitochondrial complex I deficiency, nuclear type 11, mitochondrial complex I deficiency, nuclear type 13, mitochondrial complex I deficiency, nuclear type 14, mitochondrial complex I deficiency, nuclear type 15, mitochondrial complex I deficiency, nuclear type 16, mitochondrial complex I deficiency, nuclear type 17, mitochondrial complex I deficiency, nuclear type 19, mitochondrial complex I deficiency, nuclear type 21, mitochondrial complex I deficiency, nuclear type 22, mitochondrial complex I deficiency, nuclear type 23, mitochondrial complex I deficiency, nuclear type 24, mitochondrial complex I deficiency, nuclear type 25, mitochondrial complex I deficiency, nuclear type 26, mitochondrial complex I deficiency, nuclear type 27, mitochondrial complex I deficiency, nuclear type 28, mitochondrial complex I deficiency, nuclear type 29, mitochondrial complex I deficiency, nuclear type 31, mitochondrial complex I deficiency, nuclear type 32, mitochondrial complex I deficiency, nuclear type 33, mitochondrial complex I deficiency, nuclear type 34, mitochondrial complex I deficiency, nuclear type 1, mitochondrial complex I deficiency, nuclear type 39

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

15 retrieved; paginated sample, class counts are floors:

5 uncertain significance, 5 pathogenic, 3 conflicting classifications of pathogenicity, 2 likely pathogenic

ClinVarVariant (HGVS)GeneClassificationReview
2674637NM_199069.2(NDUFAF3):c.77+1G>ALOC129936729Pathogenicno assertion criteria provided
424NM_199069.2(NDUFAF3):c.2T>C (p.Met1Thr)LOC129936729Pathogeniccriteria provided, single submitter
422NM_199069.2(NDUFAF3):c.229G>C (p.Gly77Arg)LOC129936731Pathogenicno assertion criteria provided
2674636NM_199069.2(NDUFAF3):c.302G>A (p.Ser101Asn)NDUFAF3Pathogenicno assertion criteria provided
423NM_199069.2(NDUFAF3):c.365G>C (p.Arg122Pro)NDUFAF3Pathogenicno assertion criteria provided
2585571NM_199069.2(NDUFAF3):c.127C>T (p.Gln43Ter)LOC129936730Likely pathogeniccriteria provided, single submitter
638292NM_199069.2(NDUFAF3):c.494C>T (p.Ala165Val)NDUFAF3Likely pathogeniccriteria provided, single submitter
1207415NM_199069.2(NDUFAF3):c.74C>T (p.Pro25Leu)LOC129936729Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
372432NM_199069.2(NDUFAF3):c.489_490del (p.Gly164fs)NDUFAF3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
377248NM_199069.2(NDUFAF3):c.188dup (p.Tyr63Ter)NDUFAF3Conflicting classifications of pathogenicitycriteria provided, conflicting classifications
1030419NM_199069.2(NDUFAF3):c.112G>A (p.Asp38Asn)LOC129936730Uncertain significancecriteria provided, multiple submitters, no conflicts
2159215NM_199069.2(NDUFAF3):c.336A>T (p.Ile112=)NDUFAF3Uncertain significancecriteria provided, multiple submitters, no conflicts
2434086NM_199069.2(NDUFAF3):c.517G>A (p.Gly173Arg)NDUFAF3Uncertain significancecriteria provided, single submitter
4056643NM_199069.2(NDUFAF3):c.143C>G (p.Ser48Cys)NDUFAF3Uncertain significancecriteria provided, single submitter
632420NM_199069.2(NDUFAF3):c.550C>T (p.Gln184Ter)NDUFAF3Uncertain significancecriteria provided, single submitter

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
NDUFAF3StrongAutosomal recessivemitochondrial complex I deficiency, nuclear type 185

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
NDUFAF3Orphanet:2609Isolated complex I deficiency

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
NDUFAF3HGNC:29918ENSG00000178057Q9BU61NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3gencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
NDUFAF3NADH dehydrogenase [ubiquinone] 1 alpha subcomplex assembly factor 3Essential factor for the assembly of mitochondrial NADH:ubiquinone oxidoreductase complex (complex I).

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
NDUFAF3Other/UnknownnoNDUFAF3/AAMDC, NDUF3, MTH938-like_sf

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
apex of heart1
left testis1
right testis1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
NDUFAF3280ubiquitousmarkerleft testis, right testis, apex of heart

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
NDUFAF31,332

Structural data

PDB: 0 · AlphaFold-only: 1 · No structure: 0

AlphaFold-only cohort genes (top 30 by pLDDT)

SymbolUniProtpLDDT
NDUFAF3Q9BU6179.02

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 4. Enrichment computed across 1 evidence-associated genes (1 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

PathwayCohort genesFoldFDRSample cohort genes
Complex I biogenesis1165.5×0.015NDUFAF3
Respiratory electron transport195.2×0.015NDUFAF3
Aerobic respiration and respiratory electron transport188.5×0.015NDUFAF3
Metabolism111.6×0.086NDUFAF3

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
mitochondrial respiratory chain complex I assembly1411.0×0.002NDUFAF3

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 1 of 1 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
NDUFAF300

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

SymbolAssaysType breakdown
NDUFAF34Binding:4

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1NDUFAF3

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
NDUFAF34

Clinical trials & evidence

Clinical trials

Clinical trials: 0.